- Home
- FROG vs MTSR Comparison
FROG vs MTSR Comparison
Compare FROG & MTSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FROG
- MTSR
- Stock Information
- Founded
- FROG 2008
- MTSR 2022
- Country
- FROG United States
- MTSR United States
- Employees
- FROG N/A
- MTSR N/A
- Industry
- FROG Computer Software: Prepackaged Software
- MTSR
- Sector
- FROG Technology
- MTSR
- Exchange
- FROG Nasdaq
- MTSR NYSE
- Market Cap
- FROG 3.6B
- MTSR 3.0B
- IPO Year
- FROG 2020
- MTSR 2025
- Fundamental
- Price
- FROG $40.68
- MTSR $29.60
- Analyst Decision
- FROG Strong Buy
- MTSR Strong Buy
- Analyst Count
- FROG 19
- MTSR 6
- Target Price
- FROG $40.44
- MTSR $55.25
- AVG Volume (30 Days)
- FROG 1.1M
- MTSR 1.0M
- Earning Date
- FROG 08-06-2025
- MTSR 05-12-2025
- Dividend Yield
- FROG N/A
- MTSR N/A
- EPS Growth
- FROG N/A
- MTSR N/A
- EPS
- FROG N/A
- MTSR N/A
- Revenue
- FROG $450,584,000.00
- MTSR N/A
- Revenue This Year
- FROG $19.79
- MTSR N/A
- Revenue Next Year
- FROG $15.14
- MTSR N/A
- P/E Ratio
- FROG N/A
- MTSR N/A
- Revenue Growth
- FROG 21.66
- MTSR N/A
- 52 Week Low
- FROG $22.91
- MTSR $12.30
- 52 Week High
- FROG $45.10
- MTSR $37.99
- Technical
- Relative Strength Index (RSI)
- FROG 47.22
- MTSR N/A
- Support Level
- FROG $40.55
- MTSR N/A
- Resistance Level
- FROG $42.47
- MTSR N/A
- Average True Range (ATR)
- FROG 1.62
- MTSR 0.00
- MACD
- FROG -0.53
- MTSR 0.00
- Stochastic Oscillator
- FROG 9.80
- MTSR 0.00
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
About MTSR METSERA INC
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.